The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Biomarker subgroup analyses of CodeBreaK 200, a phase 3 trial of sotorasib versus (vs) docetaxel in patients (pts) with pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC).
 
Ferdinandos Skoulidis
Stock and Other Ownership Interests - BioNTech; Moderna Therapeutics
Honoraria - ESMO; McGill Universite de Montreal; Moving Innovation and Technology; Physicans' Education Resource; RV Mais
Consulting or Advisory Role - Amgen; BeiGene; Calithera Biosciences; Guardant Health; Intellisphere; Medscape; Navire; Novartis; Tango Therapeutics
Research Funding - AIMM Therapeutics (I); Amgen (Inst); Boehringer Ingelheim (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst)
 
Adrianus De Langen
Consulting or Advisory Role - AstraZeneca (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche (Inst)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck Serono (Inst); Merus (Inst); MSD Oncology (Inst); Roche (Inst)
 
Luis G. Paz-Ares
Leadership - ALTUM Sequencing; Genomica
Honoraria - Amgen; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Janssen; Lilly; Medscape; Merck Serono; Mirati Therapeutics; MSD; Novartis; Pfizer; PharmaMar; Regeneron; Roche/Genentech; Sanofi; Takeda
Speakers' Bureau - AstraZeneca; BMS; Lilly; Merck Serono; MSD Oncology; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); BMS (Inst); Kura Oncology (Inst); MSD (Inst); Pfizer (Inst); PharmaMar (Inst)
Other Relationship - Amgen (I); Ipsen (I); Merck (I); Novartis (I); Pfizer (I); Roche; Roche (I); Sanofi (I); SERVIER (I)
 
Giannis Socrates Mountzios
Honoraria - Amgen; AstraZeneca; BMS GmbH & Co. KG; Boehringer Ingelheim; MSD; Novartis; Roche; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca/Greece; BMS GmbH & Co. KG; MSD; Novartis; Roche; Takeda
Speakers' Bureau - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca; AstraZeneca; BMS GmbH & Co. KG; Ipsen; MSD; Novartis; Roche
 
Alessandra Curioni-Fontecedro
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD Oncology; Roche; Takeda
Speakers' Bureau - Amgen; Bristol-Myers Squibb; MSD
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Roche
 
Sébastien Couraud
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; MSD Oncology; Novartis; Sanofi
Consulting or Advisory Role - Fab'entech; MAAT Pharma
Research Funding - AstraZeneca (Inst); Becton Dickinson (Inst); TRANSDIAG (Inst); Volition RX (Inst)
Travel, Accommodations, Expenses - Amgen; Laidet Medical; Roche; Takeda
Other Relationship - Inovotion
 
Annelies Janssens
Travel, Accommodations, Expenses - Roche (Inst)
 
Danilo Rocco
No Relationships to Disclose
 
Kadoaki Ohashi
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Kyowa Kirin; Lilly O.; MSD; Nippon Kayaku; Novartis
Research Funding - AstraZeneca/MedImmune; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo Pharmaceutical; Lilly O.
 
Mark David Vincent
Leadership - Aptose Biosciences
Stock and Other Ownership Interests - Aptose Biosciences
Honoraria - Amgen; ApoBiologix; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Lilly; Merck; Novartis; Roche Canada; Sanofi
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Merck; Novartis; Roche
Speakers' Bureau - AstraZeneca; Lilly
Research Funding - AstraZeneca (Inst)
Patents, Royalties, Other Intellectual Property - CEO Sarissa Inc., and patent holder of two non-commercialized patents
 
Jin-Hyoung Kang
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Lilly O.; MSD; Pfizer; Roche; Takeda; Yuhan
Speakers' Bureau - Boehringer Ingelheim; MSD; Novartis; Roche; Takeda
Research Funding - Boehringer Ingelheim (Inst); Daiichi Sankyo Pharmaceutical (Inst); Yuhan (Inst)
 
Gustavo Schvartsman
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD; Roche; Sanofi
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Roche; Sanofi; Takeda
Research Funding - Bristol-Myers Squibb (Inst)
 
Colin R Lindsay
Honoraria - Amgen
Consulting or Advisory Role - Amgen; cbpartners
Research Funding - Revolution Medicines (Inst)
(OPTIONAL) Uncompensated Relationships - Amgen; Amgen
 
Kenneth John O'Byrne
Stock and Other Ownership Interests - Carpe Vitae Pharmaceuticals; DGC diagnostics; RepLuca Pharmaceuticals
Honoraria - Amgen; Astrazeneca; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Ipsen; Janssen-Cilag; Merck; Merck Sharp & Dohme; Novartis; Pfizer/EMD Serono; Roche; Takeda; TriStar Technology Group; Yuhan
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Ipsen; Janssen-Cilag; Merck Sharp & Dohme; Novartis; Pfizer; Roche/Genentech; Sanofi; Yuhan
Speakers' Bureau - Boehringer Ingelheim; Bristol-Myers Squibb; Janssen-Cilag; Merck; Merck Sharp & Dohme; Pfizer; Roche
Patents, Royalties, Other Intellectual Property - I am named on 4 active patents, 2 published and 2 provisional (Inst)
 
Rafal Dziadziuszko
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD Oncology; Novartis; Roche/Genentech; Takeda
Consulting or Advisory Role - Karyopharm Therapeutics
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche
 
Jon A. Lykkegaard Andersen
Honoraria - GlaxoSmithKline; Lilly; Sanofi; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Merck; Novartis; Pfizer; Takeda
Research Funding - Takeda (Inst)
Travel, Accommodations, Expenses - MSD
 
Antreas Hindoyan
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Tomasz Wilmanski
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Yang Wang
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Martin H. Schuler
Honoraria - Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen-Cilag; Novartis
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Janssen Oncology; Merck Serono; Novartis; Roche; Sanofi; Takeda
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst)
Patents, Royalties, Other Intellectual Property - Highly sensitive method for mutation detection by PCR (Inst)